Talha Khan Burki. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/pathologyAdenocarcinoma/radiotherapyChemoradiotherapy/adverse effectsCombined Modality TherapyDose-Response Relationship, DrugHumansPancreatic Neoplasms/drug therapyPancreatic Neoplasms/pathologyPancreatic Neoplasms/radiotherapyProgression-Free SurvivalPyrazoles/adverse effectsPyrazoles/therapeutic usePyrimidinones/adverse effectsPyrimidinones/therapeutic use
Substances: See more » PyrazolesPyrimidinonesadavosertib
Year: 2019 PMID: 31427207 DOI: 10.1016/S1470-2045(19)30537-6
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316